Alector, Inc.

NasdaqGS ALEC

Alector, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2024: USD -1.71

Alector, Inc. EPS (Diluted) is USD -1.71 for the Trailing 12 Months (TTM) ending September 30, 2024, a -0.97% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

Alector, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -1.69, a -2.02% change year over year.
Alector, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -1.66, a -219.23% change year over year.
Alector, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -0.52, a 76.68% change year over year.
Alector, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -2.23, a -48.67% change year over year.

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Shares (Basic, Weighted)	Revenue

NasdaqGS: ALEC

Alector, Inc.

CEO	Dr. Arnon Rosenthal Ph.D.
IPO Date	Feb. 7, 2019
Location	United States
Headquarters	131 Oyster Point Boulevard
Employees	241
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Key trends

Past 5 years